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Abstract
Background: Aspirin has been recommended for the prevention of major adverse cardiovascular events (MACE,
composite of non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death) in diabetic patients
without previous cardiovascular disease. However, recent meta-analyses have prompted re-evaluation of this
practice. The study objective was to evaluate the relative and absolute benefits and harms of aspirin for the
prevention of incident MACE in patients with diabetes.
Methods: We performed a systematic review and meta-analysis on seven studies (N = 11,618) reporting on the
use of aspirin for the primary prevention of MACE in patients with diabetes. Two reviewers conducted a systematic
search of electronic databases (MEDLINE, EMBASE, the Cochrane Library, and BIOSIS) and hand searched
bibliographies and clinical trial registries. Reviewers extracted data in duplicate, evaluated the quality of the trials,
and calculated pooled estimates.
Results: A total of 11,618 participants were included in the analysis. The overall risk ratio (RR) for MACE was 0.91
(95% confidence intervals, CI, 0.82-1.00) with little heterogeneity among trials (I
2 0.0%). Secondary outcomes of
interest included myocardial infarction (RR, 0.85; 95% CI, 0.66-1.10), stroke (RR, 0.84; 95% CI, 0.64-1.11), cardiovascular
death (RR, 0.95; 95% CI, 0.71-1.27), and all-cause mortality (RR, 0.95; 95% CI, 0.85-1.06). There were higher rates of
hemorrhagic and gastrointestinal events. In absolute terms, these relative risks indicate that for every 10,000
diabetic patients treated with aspirin, 109 MACE may be prevented at the expense of 19 major bleeding events
(with the caveat that the relative risk for the latter is not statistically significant).
Conclusions: The studies reviewed suggest that aspirin reduces the risk of MACE in patients with diabetes without
cardiovascular disease, while also causing a trend toward higher rates of bleeding and gastrointestinal
complications. These findings and our absolute benefit and risk calculations suggest that those with diabetes but
without cardiovascular disease lie somewhere between primary and secondary prevention patients on the
spectrum of benefit and risk. This underscores the importance of considering individual risk in clinical decision
making regarding aspirin in those with diabetes.
Background
Cardiovascular disease is the leading cause of mortality
in patients with diabetes, accounting for an estimated
65-80% of deaths in these patients [1-3]. Although there
have been substantial reductions in cardiovascular-
related morbidity and mortality in the general
population over the last 40 years attributed to improved
treatment of cardiovascular risk factors and disease, the
same magnitude of benefit has not been observed in
those with diabetes mellitus [4,5]. It remains unclear
why certain interventions that benefit the general popu-
lation may be less effective for patients with diabetes.
A landmark observational study suggested that
patients with diabetes without prior myocardial infarc-
tion had a similar risk of coronary heart disease as
patients with prior myocardial infarction without dia-
betes [6]. As a result of the ideas introduced by this
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implementation of interventions for lowering cardiovas-
cular risk in patients with diabetes, such as the use of
aspirin therapy. However, as others have pointed out,
the widespread use of aspirin in patients with diabetes
mainly reflect “extrapolations from other high risk
groups... rather than on a comprehensive review of per-
tinent data” [7].
Several meta-analyses have explored the benefit of
aspirin therapy in the primary prevention of major
adverse cardiovascular events (MACE) among patients
with diabetes [8-13], and concluded that there is insuffi-
cient evidence to routinely recommend aspirin therapy
in patients with diabetes without known cardiovascular
disease [8-10]. While these reviews provided a robust
statistical summary of relative risk, some [8-10] did not
report or assess aspirin effects on absolute event rates
for cardiovascular and bleeding events. The latter is cru-
cial to considering the trade-off of benefit and harm
associated with aspirin. Moreover, current estimates of
benefit still remain uncertain. A collaborative meta-ana-
lysis of individual patient data suggested that there was
a net benefit of aspirin therapy for diabetic patients in
preventing serious vascular events in the six primary
prevention trials reviewed.Y e t ,i tw a sn o t e dt h a tt h e
results from three other primary prevention trials in dia-
betes did not demonstrate the same benefit [13].
In light of this uncertainty, we conducted a systematic
review and meta-analysis that included data from pri-
mary prevention trials that enrolled patients from the
general population as well as trials selecting for diabetic
patients, as a few of these [14-16] were not previously
incorporated in some of the earlier reviews [8,10], and
we sought to additionally quantify treatment effects in
absolute terms to better-inform readers of the risk-bene-
fit trade-off of aspirin therapy in patients with diabetes.
Methods
Search strategy
A comprehensive search was performed in MEDLINE
(1950 to February 2011), PubMed, EMBASE (1980 to
February 2011), and the Cochrane Library (including the
Cochrane Database of Systematic Reviews, Database of
Abstracts of Reviews of Effects, and Cochrane Central
Register of Controlled Trials), and BIOSIS. Language
restrictions were not applied, but our search was limited
to human studies and randomized clinical trials using
the Cochrane Collaboration filter [17]. We searched
titles and abstracts with the terms “diabetes mellitus,”
“primary prevention,” and “aspirin” as keywords (exp),
and Medical Subject Headings (MeSH). The Boolean
term “AND” was used to combine “diabetes mellitus”
and “aspirin” as well as to combine “primary prevention”
and “aspirin.” The final results were then combined with
the Boolean operator “OR.” Bibliographies of identified
studies and recent related meta-analyses were hand-
searched. Clinical trial registries (clinicaltrials.gov, isrctn.
com, and controlled-trials.com) were also searched for
ongoing and unpublished studies. Details of our search
strategy are included in Additional file 1.
Study selection and data abstraction
SB and AAL independently reviewed the retrieved titles
and abstracts and selected all studies reporting on the
use of aspirin, the primary prevention of cardiovascular
disease, and with original data reporting on a variety of
cardiovascular events (see below). Full text review was
then independently performed by SB and AAL for inclu-
sion of randomized trials that compared aspirin therapy
versus a cardiac-neutral comparator (e.g. placebo, vita-
mins), which enrolled adults (≥18 years old), and
patients with diabetes mellitus without previous histori-
cal or clinical evidence of cardiovascular disease. Studies
were excluded if they were secondary publications of
trials already included in the analysis, if the trial dura-
tion was twelve-months or less, or if the data (as pub-
lished) could not be extracted for diabetes-specific
outcomes. Disagreements in study inclusion between
reviewers were resolved by consensus, and quantified.
All outcome data were extracted by SB and AAL inde-
pendently, with subsequent discussion of any discrepan-
cies. Data were collected on baseline patient
characteristics, aspirin dosing and frequency, and var-
ious cardiovascular event rates (cardiovascular death,
myocardial infarction, stroke, all-cause mortality, hemor-
rhage, gastrointestinal bleeding, and other gastrointest-
inal events not resulting in bleeding). Outcomes from
each study were extracted in intention-to-treat cate-
gories, rather than per-protocol categories. Quality
assessment was performed by extracting information on
key study validity criteria [18] and a Jadad score was cal-
culated for each study [19].
Statistical analysis
We assessed and quantified statistical heterogeneity for
each outcome of interest using Cochran’s Q test and the
I
2 statistic, respectively [20]. Analyses for the primary
outcome of interest, MACE (defined as a composite of
non-fatal myocardial infarction, non-fatal ischemic
stroke, and cardiovascular death resulting from myocar-
dial infarction and ischemic stroke), and all-cause mor-
tality were performed using the Mantel-Haenszel fixed
effects model. The remainder of our analyses were per-
formed using the DerSimonian and Laird random effects
model because some heterogeneity was present. We cal-
culated risk ratios (RR) and 95% confidence intervals
(95% CIs) for MACE, total myocardial infarction, total
stroke, cardiovascular death, all-cause mortality,
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Page 2 of 11hemorrhage, gastrointestinal bleeding, and other gastro-
intestinal events not resulting in bleeding. We subse-
quently contextualized our results by calculating the
absolute risk reduction (ARR, derived by calculating the
difference between the combined control arm event rate
and the product of the pooled relative risk and the com-
bined control arm event rate), the number need to treat
(NNT) and then compared our estimated to published
data. The balance of risk and benefit was further repre-
sented by the “likelihood of being helped versus
harmed” metric (LHH, a ratio of number needed to
harm, as estimated by the Antithrombotic Trialists’
(ATT) Collaboration [13], divided by the NNT) [21,22].
Subgroup analyses were conducted to examine the
effects of aspirin dosage, allocation concealment, rando-
mization, blinding, and whether a trial exclusively
enrolled patients with diabetes on the pooled RR. We
performed meta-regression analyses using maximum
likelihood estimation. Assessment for publication bias
was performed for the main outcome of interest with
Egger’s linear regression test [23,24]. Analyses were per-
formed using Stata version 11 (StataCorp, College
Station, Texas). The study is reported according to
PRISMA guidelines [18].
Results
Study selection and evaluation
Of the 4129 citations identified in our search, fifteen
were identified for full-text review, and a total of seven
unique trials were eligible for inclusion in this study
(see Figure 1 for PRISMA flow chart). Follow-up
searches failed to identify any additional trials that met
inclusion criteria. Disagreement among the two
reviewers regarding eligibility of studies occurred on
only five occasions ( score = 0.89).
Studies included in the systematic review
Summary data from the seven randomized clinical trials
(n = 11,618) are presented in Table 1 [14-16,25-29]. The
Physicians’ Health Study (PHS) recruited male physi-
cians, approximately 2% of whom had diabetes [29], and
the Women’s Health Study (WHS) enrolled women with
approximately 3% of trial participants identified to have
diabetes [27]. The Hypertension Optimal Treatment
Figure 1 Study flow diagram.
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Page 4 of 11(HOT) trial studied whether the addition of aspirin to
antihypertensive treatment reduced the risk of MACE
compared with placebo [14,15]. The remaining four
trials [16,25,26,28] exclusively studied patients with dia-
betes, with two trials studying type 2 diabetes only
[25,28], and two trials incorporating patients with type 1
or type 2 diabetes [16,26]. Approximately half of the
participants in the Early Treatment Diabetic Retinopathy
Study (ETDRS) were reported to have a history of cardi-
ovascular disease (i.e. self-reported history of coronary
disease, heart failure, or peripheral arterial disease, as
well as patients on any beta-adrenergic antagonist, anti-
hypertensive agent, antiarrhythmic agents, digitalis, or
nitrates) [16]. The remaining six trials (as reported) did
not enroll any patients with overt cardiovascular disease.
There was substantial variability in aspirin dosages with
higher doses of 325 mg every other day in the PHS [29]
and 650 mg daily in the ETDRS [16]. Aspirin doses of
100 mg or less per day were used in the remaining five
trials: Primary Prevention Project (PPP) [28], WHS [27],
HOT [14,15], Prevention and Progression of Arterial
Disease and Diabetes Trial (POPADAD) [26], and Japa-
nese Primary Prevention of Atherosclerosis with Aspirin
for Diabetes (JPAD) [25]. Trial duration ranged from 3.6
years [28] to 10.1 years [27].
A summary of study quality indicators is presented in
Table 2. Randomization occur r e di na l ls e v e ns t u d i e s ,
but the use of allocation concealment was clearly stated
in only five of the trials [14-16,26,28,29]. All seven stu-
dies had a Jadad score of three or greater. Intention-to-
treat analysis was explicit in four trials [16,25,27,28] and
loss to follow-up was accounted for in all trials except
one [28]. Treatment in three studies was randomly
assigned according to a 2 × 2 factorial design [26-28].
The WHS [27], PPP [28], and POPADAD [26] trials
also had a vitamin or anti-oxidant component. Two
trials were open-labeled [25,28]. None of the trials
appeared to have substantial baseline differences
between patients allocated to aspirin therapy versus the
comparator-arm.
Major adverse cardiovascular events
Six trials reported data on MACE [14-16,25-28]. A total
of 612 MACE occurred among the 5565 participants
with diabetes treated with aspirin compared to 668
MACE among 5520 diabetic participants in the control
group (Table 3; Figure 2). Tests for statistical heteroge-
neity of results across the six trials revealed homogene-
ity (I
2 = 0.0%; p = 0.945). None of the individual trials
reported a significantly decreased risk of MACE among
participants assigned to aspirin. However, the pooled
effect estimate was very nearly significant with a relative
risk (RR) of 0.91 (95% CI, 0.82 to 1.00).
Myocardial infarction
A total of 406 myocardial infarctions (non-fatal and
fatal) was documented among 5840 participants in the
aspirin group compared to 457 myocardial infarctions
among the 5778 participants in the control group across
the seven trials (Table 3; Figure 2) [14-16,25-29]. Het-
erogeneity of the trial results was moderate to high (I
2 =
53.1%; p = 0.046), which may be in part due to the
WHS [27] (15% weight) and the PHS [29] (10% weight)
trials, which enrolled exclusively women and men,
respectively. The pooled risk estimate of the total avail-
able data was non-significant (RR, 0.85; 95% CI, 0.66 to
1.10). After exclusion of WHS [27] and PHS [29], het-
erogeneity substantially decreased between trials (I
2 =
14.2%; p = 0.324) with no substantial change in the
overall effect estimate (RR, 0.89; 95% CI, 0.75 to 1.06).
Table 2 Summary of quality indicators for studies assessing aspirin in patients with diabetes for the primary
prevention of major adverse cardiovascular events
Study,
Year
Allocation
Concealment
Blinding of participants
and outcome-assessors
Placebo -
controlled
Intention to
Treat Analysis
Lost to Follow
up Accounted
Potential
Baseline
Difference
JADAD Score
(Range 0-5)
PHS, 1989# Yes Yes Yes Undetermined Yes No 5
ETDRS,
1992
Yes Yes Yes Yes Yes No 4
HOT, 1998 Yes Yes Yes Undetermined Yes No 4
PPP, 2003# Yes No No* Yes Undetermined No 3
WHS,
2005#
Undetermined Yes Yes Yes Yes No 4
POPADAD,
2008
Yes Yes Yes** Undetermined Yes No 5
JPAD, 2008 No No No Yes Yes No 3
PHS: Physicians’ Health Study, ETDRS: Early Treatment Diabetic Retinopathy Study, HOT: Hypertension Optimal Treatment, PPP: Primary Prevention Project, WHS:
Women’s’ Health Study, POPADAD: Prevention and Progression of Arterial Disease and Diabetes Trial, JPAD: Japanese Primary Prevention of Atherosclerosis with
Aspirin for Diabetes, # methods papers reviewed, * and/or comparator of vitamin E 300 mg once daily, **and/or comparator of anti-oxidant tablet
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Among the 5565 participants assigned to aspirin ther-
apy, a total (non-fatal ischemic and fatal ischemic) of
201 strokes occurred, compared to 223 strokes in the
control group of 5520 participants (Table 3; Figure 2)
[11-13,20-23]. Moderate amounts of heterogeneity
between study results were quantified (I
2 = 47.4%; p =
0.091). Some heterogeneity may be explained by the
WHS (14% weight), a trial of women only and with the
greatest relative risk reduction of strokes with aspirin
[27]. The pooled RR of the results from the five trials
was non-significant (0.84; 95% CI, 0.63 to 1.11). After
exclusion of the WHS [27], heterogeneity diminished (I
2
= 0.0%; p = 0.468) and the pooled effect estimate
remained non-significant.
Cardiovascular death
Death directly attributed to cardiovascular disease was
found in 321 participants treated with aspirin, and 354
in the control group across five trials (Table 3; Figure 2)
[14-16,25,26,28]. Only JPAD, a trial of Japanese patients,
reported a statistically significant risk reduction with
aspirin therapy [25]. Moderate amounts of heterogeneity
were quantified in this analysis (I
2 = 41.1%; p = 0.148).
The pooled estimate of RR of the results from the four
trials was non-significant (0.95; 95% CI, 0.71 to 1.27).
Although further exclusion of JPAD [25] resulted in a
reduction in statistical heterogeneity (I
2 =0 . 0 % ,p=
0.507), the overall effect estimate remained broadly simi-
lar (RR, 0.93; 95% CI, 0.80 to 1.07).
All-cause mortality
A total of 533 deaths were recorded among 5027 partici-
pants treated with aspirin compared to 561 deaths in the
control arm with 5031 participants (Table 3; Figure 2)
[14-16,25,26,28]. None of the trials reported significant
reductions in risk of death associated with aspirin ther-
apy. Heterogeneity was non-significant between trials (I
2
= 0.0%; p = 0.838). The pooled effect estimate was also
non-significant (RR, 0.95; 95% CI, 0.85 to 1.06).
Drug-related side effects
Hemorrhagic complications were uncommon. A total of
81 bleeding events occurred among 3637 participants
treated with aspirin compared to 48 hemorrhagic com-
plications among the 3644 participants treated with pla-
cebo, for a pooled RR risk of 2.50 (95% CI, 0.77-8.10)
(Table 4). 48 cases of gastrointestinal bleeding were
documented among 2419 participants on aspirin com-
pared to 36 cases among 2427 in the control group (RR
2.13, 95% CI 0.63-7.25). Gastrointestinal events not
resulting in bleeding (such as dyspepsia, non-bleeding
peptic ulcers, or gastritis) occurred in 120 of 1900 parti-
cipants on aspirin compared to 98 of 1915 participants
in the control arm (RR 2.92 (0.17-50.23). None of these
differences were statistically significant (Table 4), but
statistical power was limited given the relatively low fre-
quency of these adverse events.
Absolute benefit and harm
The ARR of MACE in the reviewed studies is 1.09%
associated with aspirin therapy with a corresponding
number needed to treat (NNT) of 92 to prevent one
major cardiovascular event. The estimate of the LHH is
6 (range of 2-8).
Subgroup analysis
Subgroup analysis was performed to explore potential
sources of variability between trials. There was no statis-
tical significant effect on the pooled RR when analyzed
Table 3 Cardiovascular and mortality outcomes in studies assessing aspirin in patients with diabetes for the primary
prevention of major adverse cardiovascular events
Study and
Year
Total Patients
with Diabetes
MACE
(ASA)
MACE
(Control)
Total
Mortality
(ASA)
Total
Mortality
(Control)
CV
Mortality
(ASA)
CV
Mortality
(Control)
Total
MI*
(ASA)
Total MI*
(Control)
Total
Stroke*
(ASA)
Total
Stroke*
(Control)
PHS, 1989 533 - - - - - - 11 26 - -
ETDRS,
1992
3711 333 361 340 366 244 275 241 283 92 78
HOT, 1998 1501 47 54 40 36 23 26 11 18 20 22
PPP, 2003 1031 14 20 25 20 10 8 5 10 9 10
WHS, 2005 1027 51 55 - - - - 36 24 15 31
POPADAD,
2008
1276 127 132 94 101 43 35 90 82 37 50
JPAD, 2008 2539 40 46 34 38 1 10 12 14 28 32
MACE: major adverse cardiovascular events, ASA: aspirin, CV: cardiovascular, MI: myocardial infarction, *: non-fatal and fatal, “ - “: not reported, PHS: Physicians’
Health Study, ETDRS: Early Treatment Diabetic Retinopathy Study, HOT: Hypertension Optimal Treatment, PPP: Primary Prevention Project, WHS: Women’s’ Health
Study, POPADAD: Prevention and Progression of Arterial Disease and Diabetes Trial, JPAD: Japanese Primary Prevention of Atherosclerosis with Aspirin for
Diabetes.
Butalia et al. Cardiovascular Diabetology 2011, 10:25
http://www.cardiab.com/content/10/1/25
Page 6 of 11Figure 2 Effect of aspirin on the primary prevention of myocardial infarction (non-fatal and fatal), stroke (non-fatal and fatal),
cardiovascular death, major adverse cardiovascular events (a composite of non-fatal myocardial infarction, non-fatal stroke, and
cardiovascular death), and all-cause mortality in patients with diabetes. Relative risks (RRs) are indicated by squares with the relative weight
of each trial represented by the size of each square. 95% confidence intervals (CIs) are indicated by horizontal lines. Pooled risk estimates and
corresponding 95% CIs are represented by diamonds. Squares or diamonds to the left of the solid line indicate benefit with aspirin therapy.
JPAD = Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes; POPADAD = Prevention Of Progression of Arterial Disease And
Diabetes; WHS = Women’s Health Study; PPP = Primary Prevention Project; ETDRS = Early Treatment Diabetic Retinopathy Study; HOT =
Hypertension Optimal Treatment; and PHS = Physicians’ Health Study.
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Page 7 of 11according to aspirin dosage, allocation concealment, or
whether a trial exclusively enrolled patients with dia-
betes. Randomization and blinding (of participants or
outcome assessors) were also found to be non-signifi-
cant covariates of heterogeneity (data not shown).
Publication bias
We assessed for publication bias by Egger’sl i n e a r
regression test. The b-coefficient of the bias estimate
was not statistically significant (b-coefficient = -0.72;
95% CI, -1.52 to 0.09; p = 0.07). The PHS trial was not
included in the test for publication bias because MACE
data were not reported [29].
Discussion
This meta-analysis of seven randomized clinical trials,
combining data from 11,618 participants, indicates that
aspirin therapy in patients with diabetes leads to a 9%
relative reduction in the risk of major adverse cardiovas-
cular events, a pooled risk reduction estimate that
verges on statistical significance. The point estimates of
aspirin effect on each of the components of the MACE
composite endpoint also all favor aspirin therapy, sug-
gesting a signal of benefit, though the analyses for each
of the individual endpoints does not meet statistical sig-
nificance. Drug-related side effects were relatively
uncommon and not consistently reported across trials,
but point estimates of effect suggest a trend toward
increased risk of hemorrhage and adverse gastrointest-
inal events among participants treated with aspirin.
These results are not inherently surprising and while
consistent with other recently published meta-analyses
addressing the same clinical question [8-13], also extend
findings of prior reviews. It is not surprising that several
investigators have concurrently conducted systematic
reviews to help answer such an important, yet unre-
solved question as “Is aspirin effective at preventing car-
diovascular events in patients with diabetes who have
not had a prior event?” While other investigators
reviewing this topic have chosen to interpret statistically
non-significant benefit as no evidence of benefit [8,9],
we view the results differently and extend the findings
to provide (below) estimates of the balance of absolute
risks and benefits.
It has been clearly demonstrated in a variety of patient
populations that aspirin significantly decreases the risk
of MACE while increasing the risk of bleeding complica-
tions [13]. Aspirin use has established benefits and asso-
ciated harms and it is the relative trade-off of
cardiovascular events prevented versus bleeding events
caused by aspirin that needs to be carefully considered
on the basis of patient characteristics and individualized
estimates of cardiovascular risk [13]. Patients with estab-
lished cardiovascular disease are at greatest risk for
MACE and death, and thus benefit the most from
aspirin therapy. In contrast, the absolute benefit of
aspirin is substantially less pronounced in patients esti-
mated to be at lower risk for the primary prevention of
cardiovascular disease [13,30,31].
The pressing question is thus to consider where on
the spectrum of absolute benefit and harm patients with
diabetes without known existing cardiovascular disease
fall? To date, the answer has been somewhat elusive,
though our results shed some light on this question.
The ARR of MACE in the studies that we reviewed is
1.09% associated with aspirin therapy with a correspond-
ing NNT of 92 to prevent one major cardiovascular
event. In comparison, patients with diabetes at greatest
risk for MACE (i.e. risk approaching those in the gen-
eral population with established cardiovascular disease)
Table 4 Risk of adverse events in studies assessing aspirin in patients with diabetes for the primary prevention of
major adverse cardiovascular events
Study and Year Total Patients
with Diabetes
All
Bleeding
(ASA)
All Bleeding
(Control)
All GI
Bleeding
(ASA)
All GI
Bleeding
(Control)
Non-bleeding GI
symptoms (ASA)
Non-bleeding GI
symptoms (Control)
PHS, 1989 533 - - - - - -
ETDRS, 1992 3711 37 37 - - - -
HOT, 1998 1501 - - - - - -
PPP, 2003 1031 10 1 8 1 - -
WHS, 2005 1027 - - - - - -
POPADAD, 2008 1276 - - 28 31 73 94
JPAD, 2008 2539 34 10 12 4 47 4
Number of Events/
Number of Participants
- 81/3637 48/3644 48/2419 36/2427 120/1900 98/1915
Pooled RR (95% CI) - 2.50 (0.77-8.10) 2.13 (0.63-7.25) 2.92 (0.17-50.23)
ASA: aspirin, GI: gastrointestinal, PHS: Physicians’ Health Study, ETDRS: Early Treatment Diabetic Retinopathy Study, HOT: Hypertension Optimal Treatment, PPP:
Primary Prevention Project, WHS: Women’s’ Health Study, POPADAD: Prevention and Progression of Arterial Disease and Diabetes Trial, JPAD: Japanese Primary
Prevention of Atherosclerosis with Aspirin for Diabetes, RR = relative risk (RRs >1 indicate increase risk of an adverse event associated with aspirin).
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Page 8 of 11may have an associated NNT of 67; conversely, the
NNT may be as high as 1667 in patients at lowest risk
(i.e. risk identical to those in the general population
without cardiovascular disease) [13]. Estimates of num-
ber needed to harm (NNH) for major bleeding range
from 526 to 3333 in patients treated with aspirin for
secondary and primary prevention, respectively [13].
The balance of risk and benefit, represented by the
“likelihood of being helped versus harmed” metric
(LHH), was estimated to be 6 (range of 2-8) with a
more favorable risk-benefit balance with greater baseline
risk. As such, for every 10,000 diabetic patients treated
w i t ha s p i r i n ,a p p r o x i m a t e l y1 0 9M A C Em a yb ep r e -
vented at the expense of 19 major bleeding events with
no significant overall mortality benefit.
In this context, the fundamental question relating to
patients with diabetes without cardiovascular disease is
consideration of whether they are more like the general
population without cardiovascular disease (i.e. “primary
prevention cases”), or more in keeping (in terms of risk)
with patients who have been included in secondary pre-
vention studies. Our calculation of absolute benefit
would suggest that those with diabetes but without
prior cardiovascular disease lie in an intermediate posi-
tion between a primary and secondary prevention on
the spectrum of risk and benefit.
This invokes the controversial question of whether
diabetes is a “coronary disease equivalent.” There is
widespread acceptance that diabetes is a major risk fac-
tor for cardiovascular disease [2,32-34], but there have
been varying estimates of absolute risk [3]. In 1998,
Haffner et al. found that patients with diabetes without
prior myocardial infarction had a similar risk of coron-
ary heart disease as patients with prior myocardial
infarction without diabetes (i.e. affirming the “coronary
disease equivalent” theory) [6]. However, at least twelve
subsequent observational studies have reported conflict-
ing results compared to the initial Finnish study [3], and
a recent systematic review has presented data arguing
against the notion of diabetes being a coronary-risk
equivalent [3]. Although the literature uniformly agrees
that patients with diabetes are at increased risk of cardi-
ovascular events, it now suggests that the absolute risk
is less than previously thought, and may explain why
the benefit of some evidence-based “secondary preven-
tion” treatments like aspirin are less marked when
applied to patients with diabetes in a population-based
manner.
In considering our review findings, there is a need to
consider pathophysiological factors and a potential mod-
ifying effect of diabetes on aspirin efficacy. Patients with
diabetes are felt to be at higher risk of atherothrombotic
events because of endothelial dysfunction, impaired
fibrinolysis, increased levels of circulating coagulation
factors, and high platelet reactivity [35]. However,
aspirin may have a dampened effect in some diabetic
patients in preventing platelet aggregation [36-38].
Emerging experimental studies are now demonstrating
the phenomenon of “resistance” to aspirin, which
appears to have a greater prevalence among patients
with diabetes [35]. Aspirin resistance has been corre-
lated to long-term adverse outcomes with increased cor-
onary heart disease, stroke, and peripheral vascular
disease risk [35]. Whether higher doses of aspirin may
translate to improved clinical outcomes in the setting of
aspirin resistance, or if another antiplatelet agent is
superior remains unclear.
There are currently two major ongoing trials, collectively
enrolling more than 15,000 participants, evaluating the
role of aspirin in patients with diabetes without prior car-
diovascular events: Aspirin and Simvastatin Combination
for Cardiovascular Events Prevention Trial in Diabetes
(ACCEPT-D) [39] and A Study of Cardiovascular Events
in Diabetes (ASCEND) [40]. In addition to exploring the
role of aspirin in the prevention of cardiovascular events
in patients with diabetes, these trials will help elucidate
which patients with may be at greatest risk, and thus
derive the most benefit from aspirin therapy.
Strengths and limitations
There are limitations to our study. Firstly, we were only
able to incorporate a total of seven trials in our analysis,
and quantified moderate amounts of heterogeneity
among trials for the outcomes of interest. The trials of
interest varied greatly when comparing patient popula-
tions, geographic locale, years of study, and design.
Moreover, pooling of data was limited by inconsistent
reporting of baseline characteristics and outcomes, dif-
ferences in the metrics of reported values, and variability
in definitions of the measured outcomes of interest (e.g.
major bleeding). Statistically combining significantly het-
erogeneous data may be problematic. However, we were
able to account for most of the heterogeneity in the sec-
ondary outcomes of interest by performing a sensitivity
analysis and excluding specific trials from the secondary
analysis. Exclusion of these trials did not meaningfully
affect the pooled effect estimates. Further, our estimates
of harm were derived from randomized studies of treat-
ment efficacy. The decision to use only randomized trial
data was made a priori and was based on the fact that
rigorously conducted trials provide the most robust effi-
cacy data. Consequently, we did not incorporate data
from observational studies which may have enrolled
more patients, provided longer follow-up, and been
more reflective of harm associated with treatment.
Lastly, the subgroup analysis and meta-regression we
performed was underpowered, limited by the seven trials
identified for this study. Therefore, the subgroup
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Page 9 of 11analysis is merely hypothesis-generating, and caution
should be employed not to over-interpret the results.
Conclusions
Our systematic review summarizes the current state of
knowledge regarding aspirin effects on risk of MACE
and bleeding. While less than definitive, the body of lit-
erature indicates, somewhat predictably, that aspirin
does reduce the risk of cardiovascular events while caus-
ing a trend toward higher rates of bleeding and gastroin-
testinal complications. The trade-off of these benefits
and harms, in absolute terms, suggests that the diabetes
patient without cardiovascular disease lies somewhere
between primary versus secondary prevention patients
on the spectrum of benefit and risk. We now await the
results of ACCEPT-D [39] and ASCEND [40] to help
derive more definitive estimates of absolute benefit and
harm associated with aspirin, and more refined patient-
specific estimates of the risk-benefit trade-offs.
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